Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Inclusion Criteria: * Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both eyes. Exclusion Criteria: * Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or any of the ingredients in the study drug. * Subjects with known contraindications to NO treatment. * Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period. * Subjects who are unable to discontinue the use of all topical ophthalmic medications, including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period. * Subjects with any condition that prevents reliable applanation tonometry in either eye. * Subjects with glaucoma in either eye. * Subjects with any condition that prevents clear visualization of the fundus. * Subjects who are monocular. * Subjects with aphakia in either eye. * Subjects with an active corneal disease in either eye. * Subjects with severe dry eye in either eye. * Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye. * Subjects with any intraocular infection or inflammation within 3 months (90 days) prior to Visit 1 (Screening). * Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to Visit 1 (Screening). * Subjects with a history of incisional ocular surgery or severe trauma.